Ipsos launches GLP-1 PersonaBot, designed to support companies’ understanding of the consumer obesity treatment market
Ipsos’ latest AI-powered innovation offers unparalleled insights into the fast-moving consumer obesity treatment market – while reinforcing Ipsos’ position at the forefront of AI applications in market research.
Leveraging the framework of Ipsos PersonaBot, GLP-1 PersonaBot provides AI segment personas derived from Ipsos’ Global Consumer Obesity Monitor. Subscribers can ‘converse’ with these target segments in real-time, gaining actionable intelligence to drive informed, consumer-centric strategies.
GLP-1 PersonaBot delivers:
- Depth – – Allows engagement with five distinct AI personas representing this growing market, offering nuanced insights into attitudes, behaviors, and preferences.
- Accessibility – Designed for cross-team utilization, it allows multiple stakeholders to interact with segment personas in real-time.
- Actionability - Provides immediate, data-driven insights to inform decision-making across R&D, marketing, and product innovation.
Key applications include:
- Identifying and prioritizing high-potential segments
- Informing R&D and product positioning
- Accelerating uptake of product innovations
- Tailoring messaging and engagement strategies
- Optimizing channel mix for different consumer cohorts
GLP-1 PersonaBot from Ipsos has multiple applications for GLP-1 manufacturers, and for companies across sectors monitoring the transformative impact of new obesity medications on customer needs.
For more GLP-1 insights, please check out our latest POV: Can GLP-1s rewrite our evolutionary story?
